| Indication |
Phase |
Sample Size |
Study
Design/Activity |
| Diabetes |
2 |
150 |
Multi-center, randomized
study |
| Diabetes |
3 |
500 |
Multi-center,
double-blind, placebo-controlled, parallel group study |
| Diabetes |
3 |
500 |
Multi-center,
double-blind, placebo-controlled, parallel group study |
| Human Growth Hormone |
4 |
100 |
Multi-center, randomized study |
| Rare Genetic
Disease |
N/A |
300 |
Preparation
of an Integrated Summary of safety (ISS) for a rare genetic
disease (orphan indication) submitted to FDA |
| Rare Genetic
Disease |
N/A |
300 |
Preparation
of an ISS for a rare genetic disease (orphan indication)
submitted successfully to EMEA |
